In the competitive field of Cancer Drugs, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Cancer Drugs technology and learn how to protect your intellectual property.

Get complete Patent Opposition Report for Cancer Drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Cancer Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Cancer Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Cancer Drugs industry

EP3217983Enhancement Of Tumor Response To Chemotherapy By Activation Of The Asmase/Ceramide Pathway Through Timed Administration Of A Short-Acting Anti-Angiogenic AgentMEMORIAL SLOAN KETTERING CANCER CENTERJan 31, 2025HAMM&WITTKOPP PATENTANWALTE PARTMBB
EP3270966Combination Of Hdac Inhibitor And Anti-Pd-1 Antibody For Treatment Of CancerSYNDAX PHARMACEUTICALSJan 31, 2025MAIWALD
EP3515475Chimeric Antigen Receptor (Car) That Targets Chemokine Receptor Ccr4 And Its UseTHE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSJan 30, 2025WEICKMANN & WEICKMANN PARTMBB
EP3215166Altering Gene Expression In Cart Cells And Uses ThereofTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAJan 24, 2025STRAWMAN
EP3215166Altering Gene Expression In Cart Cells And Uses ThereofTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAJan 23, 2025MAIWALD
EP2662094Cylodextrin Complexation Methods For Formulating Peptide Proteasome InhibitorsONYX THERAPEUTICSJan 17, 2025BRAND MURRAY FULLER
EP3038611Novel 2,4-Dinitrophenol Formulations And Methods Using SameYALE UNIVERSITYJan 17, 2025MITO PHARMACEUTICALS
EP3565542Polymorphic Forms Of Rad1901-2HclRADIUS PHARMACEUTICALSJan 10, 2025TEVA PHARMACEUTICAL INDUSTRIES
EP2662094Cylodextrin Complexation Methods For Formulating Peptide Proteasome InhibitorsONYX THERAPEUTICSJan 9, 2025FRESENIUS KABI DEUTSCHLAND
EP3888674Treatment Of Cancer Using Anti-Cd19 Chimeric Antigen ReceptorNOVARTISJan 3, 2025J A KEMP

To stay ahead in the competitive Cancer Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Cancer Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2478907Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
EP2962690Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE15
EP2493466Mar 10, 2021Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMA13
EP3725778Aug 18, 2021Formulations Of EnzalutamideMEDIVATION PROSTATE THERAPEUTICS11
EP3078667Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
EP3342411Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerNOVARTIS10
EP3616720Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentOSAKA UNIVERSITY10
EP3322731Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB9
EP3351246Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTIS9
EP2269603May 20, 2015Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTIS9